Clear Street’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Clear Street’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$79.1M	Buy	+500,000	New	+$67.6M	0.2%	56

Other funds holding XBI

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

MSR

Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Clear Street's XBI Position: Q2 2026 in Review

Clear Street opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 500,000 shares worth $79.1M. The stake represents 0.2% of the portfolio and ranks #56 among its holdings.

692 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Clear Street held 500,000 shares of State Street SPDR S&P Biotech ETF worth $79.1M as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Clear Street position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.2% of Clear Street's portfolio in Q2 2026, its #56 holding.
692 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Clear Street's 13F filing for Q2 2026, filed 12 Aug 2026.